Work

Regulação molecular do nicho neurogénico hippocampal na depressão e pela ação de antidepressivos: Pistas de um modelo animal de stress crónico moderado

Year: 2016
Type: dissertation
Abstract: Depression is a complex multidimensional disorder affecting around 20% of the world population. Nevertheless, its pathophysiology is still incompletely understood. Currently available antidepressant treatments are ineffective in a significant proportion of the depressed patients and relapse rates are high, emphasizing the need for better therapeutic strategies. Depression is thought to result from the interplay between genetic predisposition and environmental factors, such as stress, a major precipitating factor for depression. Depressed individuals and chronic stress animal models of depression present impairments in several systems, including neurotransmitters, neuroimmune, endocrine systems and neurotrophic factors. Adult brain retains the capacity to adapt and re-organize neural networks in response to stimuli. This ability to change occurs in several brain regions and is called neural plasticity. Neural plasticity phenomena include synapto-dendritic changes and the generation of new cells. Neural plasticity impairments in specific brain regions are involved in the pathophysiology of depression. One of these regions is the hippocampus, which is involved in several forms of memory and in stress response. Moreover, the hippocampus comprises one of the few brain regions in the adult brain where neurogenesis occurs, the dentate gyrus (DG). Previous works showed that decreased cell genesis and dendritic morphology alterations are detected in the hippocampus of depressed individuals and animal models of depression, whereas antidepressant treatment prevents these changes. Here, we used a validated rat model of depression, the unpredictable chronic mild stress (uCMS), to explore the molecular underpinnings of neural plasticity in the hippocampal DG (hDG), in the context of depression and antidepressant treatment. For that, in a first study we performed a transcriptome analysis, in the hDG of untreated depressive-like animals and after chronic treatment with either fluoxetine, imipramine, tianeptine or agomelatine. Behavioral characterization and neuromorphological analysis in the DG revealed that all antidepressants, except agomelatine, were able to reverse the depressive-like profile and the dendritic plasticity impairments induced by uCMS. UCMS-exposure produced molecular changes that were partly reversed by antidepressants. Interestingly, agomelatine reversed less uCMS-induced changes compared to other treatments. In general, fluoxetine impacted more on neurons to reduce the expression of pro-inflammatory response genes, promoting the expression of cell metabolism-related molecules. Imipramine and tianeptine presented similar molecular profiles, promoting pathways related to cellular protection. Agomelatine produced changes in several pathways, namely on Rho-GTPase-related pathways, impacting on neurons and oligodendrocytes. In summary, antidepressants belonging to different pharmacological classes generated distinct molecular profiles that may be useful in different clinical contexts. In a second study, we aimed to assess the cell cycle mechanisms regulating hippocampal cell proliferation in the context of depression and antidepressant treatment. For that we used both in vivo - uCMS rat model -and in vitro - rat hippocampal-derived neurospheres - approaches. UCMS-exposed animals presented decreased proliferation and generation of newborn neurons that were reversed by fluoxetine. In our in vivo model, results suggest that uCMS-exposure produces a cell cycle arrest in the hDG progenitor cells that is accompanied by decreased levels of cyclins D1, E and A expression. Chronic fluoxetine treatment reversed the G1 phase arrest and increased cyclin E expression. Dexamethasone (DEX), used to mimic the elevation of glucocorticoids after chronic stress, decreased proliferation in vitro, whereas the administration of serotonin (5-HT), a neurotransmitter involved in the actions of fluoxetine, partly reversed this decrease. DEX also induced a G1-phase arrest, decreasing the expression of cyclins D1, cyclin D2 and Cdk6, while increasing p27 expression. 5-HT treatment partly reversed the G1-phase arrest and restored the expression of cyclin D1 and Cdk6. These results suggest that the anti-proliferative actions of chronic stress in the adult hDG result from a glucocorticoid-mediated G1-phase arrest in the progenitor cells that may be overcome by antidepressant treatment. Together, these findings contribute to the identification of novel molecular players and targets underlying neural plasticity phenomena in the hDG in the context of depression, unravelling unique properties of different classes of antidepressant. This knowledge may help paving the way for the implementation of more personalized treatments and open new avenues for the development of novel antidepressant strategies. Future studies will further disclose the molecular changes in this and other brain regions implicated in depression and hopefully provide clues for forthcoming translational approaches in depressive patients.
Author: Patrício, Patrícia Carvalho
Language: English
Open Access status: green
OpenAlex ID: W7084287696
Cites:
Cited by:
Related to: 10